Tidal Investments LLC boosted its stake in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 447.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,102 shares of the biopharmaceutical company’s stock after purchasing an additional 19,696 shares during the quarter. Tidal Investments LLC’s holdings in Insmed were worth $1,759,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in INSM. Ally Bridge Group NY LLC boosted its position in shares of Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after acquiring an additional 21,833 shares during the period. Orion Portfolio Solutions LLC boosted its position in shares of Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 9,170 shares during the period. Vestal Point Capital LP boosted its position in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the period. TimesSquare Capital Management LLC bought a new stake in shares of Insmed in the third quarter valued at approximately $35,322,000. Finally, &PARTNERS bought a new stake in shares of Insmed in the second quarter valued at approximately $300,000.
Insmed Stock Up 0.6 %
Shares of NASDAQ INSM opened at $73.85 on Wednesday. The stock has a market cap of $13.21 billion, a PE ratio of -13.31 and a beta of 1.10. The business has a fifty day moving average of $72.44 and a two-hundred day moving average of $71.56. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Bank of America upped their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. upped their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $83.67.
Get Our Latest Research Report on INSM
Insmed Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading
- Five stocks we like better than Insmed
- Upcoming IPO Stock Lockup Period, Explained
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- The Basics of Support and Resistance
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- 5 discounted opportunities for dividend growth investors
- Salesforce’s Clear Path to $400 and Beyond
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.